Amylyx Pharmaceuticals Management
Management criteria checks 3/4
Amylyx Pharmaceuticals' CEO is Josh Cohen, appointed in Jan 2013, has a tenure of 11.25 years. total yearly compensation is $7.18M, comprised of 7.5% salary and 92.5% bonuses, including company stock and options. directly owns 4.14% of the company’s shares, worth $5.62M. The average tenure of the management team and the board of directors is 3.3 years and 3.3 years respectively.
Key information
Josh Cohen
Chief executive officer
US$7.2m
Total compensation
| CEO salary percentage | 7.5% |
| CEO tenure | 11.3yrs |
| CEO ownership | 4.1% |
| Management average tenure | 3.3yrs |
| Board average tenure | 3.3yrs |
Recent management updates
Recent updates
Analysts Just Shaved Their Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Forecasts Dramatically
Mar 12
An ALS Drug Fails Again
Mar 09Amylyx Pharmaceuticals: Q4 Earnings Insight And PHOENIX Trial Implications
Feb 23Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) 27% Price Boost Is Out Of Tune With Revenues
Feb 23Take Care Before Jumping Onto Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Even Though It's 34% Cheaper
Nov 10Amylyx Pharmaceuticals (NASDAQ:AMLX) Is In A Strong Position To Grow Its Business
Sep 24This Just In: Analysts Are Boosting Their Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Outlook for This Year
May 16Amylyx Pharmaceuticals (NASDAQ:AMLX) Is In A Strong Position To Grow Its Business
Apr 20Earnings Update: Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Just Reported And Analysts Are Boosting Their Estimates
Mar 16Amylyx Pharmaceuticals (NASDAQ:AMLX) Is In A Good Position To Deliver On Growth Plans
Dec 19Amylyx Pharmaceuticals prices $214.2M upsized stock offering at $32.00/share
Oct 07Amylyx ALS Drug Approval: Unexpected, Welcome, And Conditional - May Put Share Price In Stasis
Sep 30Amylyx Pharma stock surges 81% after ALS drug gets FDA advisers backing
Sep 08Amylyx plunges 28% after FDA briefing documents on ALS drug
Sep 02We're Not Very Worried About Amylyx Pharmaceuticals' (NASDAQ:AMLX) Cash Burn Rate
Aug 29Amylyx Pharmaceuticals GAAP EPS of -$0.93 misses by $0.01
Aug 11Amylyx Pharmaceuticals says ALS treatment Albrioza now available in Canada
Jul 29Amylyx partners with Sunnybrook Research to identify neurodegenerative disease candidates
Jul 18Amylyx: Thoughts Ahead Of September 29 PDUFA In Amyotrophic Lateral Sclerosis
Jul 04Amylyx Pharmaceuticals: Share Price Bump On Canada Approval For ALS Drug May Not Last
Jun 17We're Keeping An Eye On Amylyx Pharmaceuticals' (NASDAQ:AMLX) Cash Burn Rate
May 07Amylyx: Crucial Advisory Committee Meet Tomorrow, Approval Chancy
Mar 29CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | US$49m |
| Sep 30 2023 | n/a | n/a | US$2m |
| Jun 30 2023 | n/a | n/a | -US$73m |
| Mar 31 2023 | n/a | n/a | -US$149m |
| Dec 31 2022 | US$7m | US$539k | -US$198m |
| Sep 30 2022 | n/a | n/a | -US$184m |
| Jun 30 2022 | n/a | n/a | -US$153m |
| Mar 31 2022 | n/a | n/a | -US$121m |
| Dec 31 2021 | US$1m | US$418k | -US$88m |
| Sep 30 2021 | n/a | n/a | -US$68m |
| Dec 31 2020 | US$671k | US$370k | -US$42m |
Compensation vs Market: Josh's total compensation ($USD7.18M) is above average for companies of similar size in the US market ($USD681.24K).
Compensation vs Earnings: Josh's compensation has been consistent with company performance over the past year.
CEO
Josh Cohen (31 yo)
11.3yrs
Tenure
US$7,178,416
Compensation
Mr. Joshua B. Cohen also known as Josh, co-founded Amylyx Pharmaceuticals, Inc. in 2013 and has been its Co-Chief Executive Officer and Director since January 2014. Mr. Cohen served as Chairman of the Boar...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 11.3yrs | US$7.18m | 4.14% $ 5.6m | |
| Co-Founder | 11.3yrs | US$7.18m | 4.05% $ 5.5m | |
| Chief Financial Officer | 3.3yrs | US$3.66m | 0.12% $ 167.6k | |
| Chief Legal Officer & General Counsel | 2.2yrs | US$6.11m | 0.0087% $ 11.7k | |
| Chief Technical Operations Officer | no data | no data | no data | |
| Head of Investor Relations & Communications | no data | no data | no data | |
| Head of Global Marketing | 3.3yrs | no data | no data | |
| Chief Human Resources Officer | less than a year | no data | no data | |
| Head of Canada & GM | 3yrs | no data | no data | |
| Head of Global Market Access | 3.3yrs | no data | no data | |
| Global Head of Regulatory Affairs | 3.7yrs | no data | no data | |
| VP & Head of Global Medical Affairs | 3.9yrs | no data | no data |
3.3yrs
Average Tenure
42yo
Average Age
Experienced Management: AMLX's management team is considered experienced (3.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 10.3yrs | US$7.18m | 4.14% $ 5.6m | |
| Co-Founder | 10.3yrs | US$7.18m | 4.05% $ 5.5m | |
| Company Secretary & Member of Scientific Advisory Board | no data | no data | no data | |
| Special Advisor & Member of Advisory Board | 3.3yrs | US$51.24k | no data | |
| Independent Chairman of the Board | 9.3yrs | US$386.85k | 1.12% $ 1.5m | |
| Chairman of The Scientific Advisory Board | no data | no data | no data | |
| Board Observer & Advisor | 6.8yrs | no data | no data | |
| Independent Director | 1.1yrs | no data | 0.0074% $ 10.0k | |
| Independent Director | 2.8yrs | US$352.09k | 0% $ 0 | |
| Director | less than a year | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 3.1yrs | US$354.15k | 0.0058% $ 7.9k |
3.3yrs
Average Tenure
61.5yo
Average Age
Experienced Board: AMLX's board of directors are considered experienced (3.3 years average tenure).